Cue Biopharma (NASDAQ:CUE) Trading Down 0.7% – Time to Sell?

Cue Biopharma, Inc. (NASDAQ:CUE)’s stock price fell 0.7% during mid-day trading on Monday . The company traded as low as $29.44 and last traded at $30.95. Approximately 135,939 shares traded hands during mid-day trading, an increase of 9% from the average session volume of 125,288 shares. The stock had previously closed at $31.16.

Analyst Ratings Changes

CUE has been the topic of a number of research analyst reports. Weiss Ratings upgraded Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen upgraded Cue Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cue Biopharma has an average rating of “Sell”.

Cue Biopharma Trading Up 3.4%

The firm has a fifty day simple moving average of $27.39 and a 200-day simple moving average of $181.77. The stock has a market cap of $145.27 million, a price-to-earnings ratio of -6.28 and a beta of 2.45.

Cue Biopharma (NASDAQ:CUE) last released its earnings results on Thursday, May 14th. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($3.30) by $2.22. The company had revenue of $5.69 million during the quarter, compared to analysts’ expectations of $2.50 million. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.

Institutional Trading of Cue Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GC Wealth Management RIA LLC lifted its position in Cue Biopharma by 35.0% during the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock valued at $1,415,000 after purchasing an additional 1,200,000 shares during the period. Boothbay Fund Management LLC grew its position in shares of Cue Biopharma by 15.3% during the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after buying an additional 93,333 shares during the period. Texas Capital Bank Wealth Management Services Inc grew its position in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after buying an additional 407,568 shares during the period. Stifel Financial Corp raised its stake in shares of Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after buying an additional 50,000 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Cue Biopharma during the third quarter worth approximately $62,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.